Elejalde Syndrome

Back

Background

Elejalde syndrome (ES) was first described in 1977[1] in 3 consanguineous families in Columbia. Elejalde syndrome is also referred to as neuroectodermal melanolysosomal disease.[2] The largest series of patients has been reported in Mexico. It has been suggested that Elejalde syndrome is the same disease entity as Griscelli syndrome type 1 caused by MYO5A gene mutations.[3] Still, the exact basis for Elejalde syndrome remains to be defined.[4]  Elejalde syndrome continues to be discussed by clinicians who assess children with silver hair.[5, 6]

Silvery hair and CNS dysfunction characterize this rare autosomal recessive syndrome. The main cutaneous features of Elejalde syndrome include silver-leaden (silvery) hair and intense tanning after sun exposure (bronze skin color on sun-exposed areas).

Severe neurologic impairment (eg, seizures, severe hypotonia, mental retardation) either is congenital or develops during childhood. The immune system is not impaired. Elejalde syndrome has a wide spectrum of ophthalmologic abnormalities.

Large granules of melanin are unevenly distributed in the hair shaft. Abnormal melanocytes, melanosomes, and abnormal inclusion bodies may be present in fibroblasts. Elejalde syndrome must be distinguished from Chédiak-Higashi syndrome[7, 8]  (CHS) and Griscelli syndrome (GS).

Elejalde syndrome (Online Mendelian Inheritance in Man [OMIM] entry #256710[3] ) should not be confused with another Elejalde syndrome (OMIM entry 200995), also known as acrocephalopolydactylous dysplasia. A number sign (#) denotes the entry for Elejalde syndrome because neuroectodermal melanolysosomal disease, or Elejalde disease, and Griscelli syndrome type 1 (GS1; 214450) are really the same entity. GS1 is caused by mutation in the MYO5A gene (160777).[9]

Modern genetic studies have more firmly fixed the relative place of Elejalde in children and adults.[10, 11]

While no new cases have been reported in 2012, Elejalde syndrome remains in the differential diagnosis of CHS and GS and was actively discussed in several papers when assessing the combination of silver hair and immunodeficiency.[12, 13]

Saini et al equated GS1 with Elejalde syndrome.[14] They noted the case of a 3-year-old boy with a viral infection who experienced fever, regression of neurological function, focal seizures, and altered sensorium. Physical findings included spastic quadriparesis. extensor plantars, silvery-gray hair, bilateral papilledema, hepatosplenomegaly, and brisk muscle-stretch reflexes. The child was noted to have normal retinae, irises, and skin pigmentation. GS1 (also known as Elejalde syndrome) was confirmed using hair microscopy.

Pathophysiology

The pathophysiology of Elejalde syndrome is not fully understood. Some have stated that it is the result of a distorted gene product responsible for early melanin formation. The abnormal melanosomes form leaden-to-silvery–colored hair and cause defective CNS function. Molecular defects that underlie a variety of pigmentary disorders have been defined and provide a framework for the understanding of syndromes such as Elejalde syndrome.[15]

In 2000, Lambert et al[16] stated that the neurologic abnormalities seen in Elejalde syndrome are probably not caused by abnormal neuromelanin deposition. Instead, Lambert et al posited that the neurologic abnormalities may be linked to impaired function of a molecule playing a common role in melanocytic and neuronal organelle function. Lambert et al believe that the likely candidate genes for Elejalde syndrome must be sought in the variety of genes involved in organellogenesis and intracellular trafficking.

In 2000, Sanal et al[17] referred to neuroectodermal melanolysosomal disease as an allelic variant of Griscelli syndrome. In 2002, Anikster et al[18] suggested that families previously thought to have Griscelli syndrome due to mutations in the MYO5A gene (OMIM entry #160777) may in fact have had Elejalde syndrome.

The absence of immunologic defects allows Elejalde syndrome to be distinguished from Griscelli syndrome (at least type 1). Sanal et al[17] suggest that ashen is a mouse model of Elejalde syndrome; however, in 2000, Wilson et al[19] showed that a mutated Rab27a gene, not the MYO5A gene, causes the pathology of the ashen mouse. This discussion is summarized from the OMIM page on this disease (see OMIM Elejalde syndrome).[3]

Myosin-Va is a very important gene in the brain.[20]  Its gene product is involved in the transport mechanism of the endoplasmic reticulum with the Purkinje neuron dendritic spines.[21] It is involved with cerebellar learning function and neural plasticity.[22]

Epidemiology

Frequency

United States

Elejalde syndrome is extremely rare, with fewer than 20 patients reported.

International

In 1977, Elejalde et al[1] described a new pigment mutation in 2 males and 1 female, each from a consanguineous marriage in an inbred Colombian kindred. Whether the disease is more common in Columbia is unknown. The large series of patients with Elejalde syndrome is from Mexico, but whether this finding indicates an increased incidence is unknown.

Afifi et al[23] reported on an Egyptian male patient with Elejalde syndrome who had silvery hair since birth, generalized hypopigmentation, severe primary CNS dysfunction, and normal hematological and immunologic profiles.

A 2011 survey of hypopigmentary diseases in India noted no cases of Elejalde syndrome.[24]

Race

A racial predilection is not known.

Sex

Elejalde syndrome is an autosomal recessive disease; therefore, no difference in sexual frequency exists.

Age

Elejalde syndrome usually starts to manifest during infancy. In 1999, Duran-McKinster et al[25] noted that the age at onset of neurologic signs ranged from 1 month to 11 years.

In 2001, Ivanovich et al[26] noted a 12-year-old boy with Elejalde syndrome and compared this condition with Chédiak-Higashi syndrome and Griscelli syndrome. This boy demonstrated severe developmental delay, seizure activity, exotropia, nystagmus, ataxia, and silvery-gray hair and eyebrows. The skin of this patient was not hypopigmented; rather, it was bronzed with diffuse freckling in sun-exposed areas. The boy had no history of recurrent infections, and results from immunologic studies were normal. Ivanovich et al[26] suggested that this patient is reportedly the oldest living child with Elejalde syndrome. It is not clear if the patient had Elejalde syndrome.

Prognosis

All cases of Elejalde syndrome but one have been reported as being fatal; therefore, the prognosis is suboptimal. Patients with Elejalde syndrome undergo neurologic collapse and eventually are not able to move or care for themselves.

Death occurs from neurologic collapse in childhood. One report noted deaths of children aged 3 months to 4 years. Another report[26] noted that a patient with Elejalde syndrome was alive at age 12 years. Another report noted that one patient with Elejalde syndrome died of respiratory infection at age 5.5 years.

The main morbidity comes from neurologic dysfunction and psychomotor regression and dysfunction.

History

Children with Elejalde syndrome can manifest with disease as early as 1 month of life or in early childhood. The skin and neurologic systems are the most commonly affected. Psychomotor impairment may have 2 forms of presentation: congenital or infantile.

Some patients with Elejalde syndrome have severe mental retardation since the first months of life. They do not seem to recognize their parents, they have almost complete absence of movements, they are severely hypotonic, and they are unresponsive to external stimuli.

Another group of patients had no history of early neurologic impairment and developed normally. By the time the patients were aged 3-11 years, they developed several rapidly regressive psychomotor processes. They were unable to speak, walk, and feed themselves, and they were bedridden.

Other symptoms include severe migraine headaches followed by hemiparesis, leg weakness progressing to severe hypotony involving the entire body, atactic cerebellar movements progressing into an inability to maintain muscular tone of the neck, profound hypotonia, and a resultant inability to walk or to speak.

Once the neurologic alterations occur, most patients have convulsive episodes. Neuromuscular disorders include constant severe generalized hypotonia as well as hyperactive deep tendon reflexes.

In a study by Duran-McKinster et al in 1999,[25] the age at onset of neurologic signs ranged from 1 month to 11 years. The manifestations of the brain pathology of Elejalde syndrome consisted of severe muscular hypotonia, ocular alterations, and seizures. Duran-McKinster et al[25] note mental retardation that first occurred before age 6 months in 4 patients. Psychomotor development was appropriate in 3 patients; however, the patients suddenly demonstrated a regressive neurologic process. Four patients died between age 6 months and 3 years after neurologic dysfunction began.

Others have noted spastic hemiplegia or quadriplegia and seizures that decrease over time.

Physical Examination

Immune impairment is absent. Ophthalmologic findings include nystagmus, diplopia, and congenital amaurosis. Respiratory infections can occur, but their relationship to the disease is unclear. The scalp and body hair, the eyebrows, and the eyelashes have a silvery color. The skin can have a bronze or deep-tan color after sun exposure. Chen[27] noted that omphalocele can be a finding in persons with Elejalde syndrome.  "Silvery hair syndrome” occurs in both  Elejalde syndrome.and Griscelli syndrome, so to distinguish the two other signs and symptoms need to be assessed.[28]

Laboratory Studies

Immunologic test results are normal for persons with Elejalde syndrome. New degranulation assays might aid in prompt diagnosis of diseases like Elejalde syndrome.[29]

Imaging Studies

Results of CT and MRI of the brain are usually abnormal in Elejalde syndrome patients, and findings include the following:

Other Tests

Findings on electroencephalograms are usually abnormal in Elejalde syndrome patients.

Histologic Findings

Upon microscopic examination, hair samples from patients with Elejalde syndrome demonstrate irregular clumps of melanin.

The skin melanocytes of patients with Elejalde syndrome possess irregularly shaped melanosomes marked by an incomplete transfer-block toward surrounding keratinocytes. A few abnormal melanolysosomes occur in obligatory heterozygotes.

In the bone marrow, the abnormal structures have been noted to be excreted into the extracellular space. Ultrastructurally, abnormal inclusion bodies can be noted in fibroblasts, bone marrow histiocytes, and lymphocytes.

In one patient, a biopsy of leptomeningeal tissue and the cerebellar cortex revealed a thickened wall of meningeal membranes with a dense inflammatory infiltrate composed of mainly lymphocytes, scanty plasma cells, and macrophages.

The tissue of the cerebellar cortex in his patient showed a dense inflammatory infiltrate predominantly surrounding small veins and venules. Examination did not reveal necrotizing vasculitis. Cerebellar folia revealed multifocal necrosis in the entire width. Examination did not demonstrate viral inclusions or periodic acid-Schiff–positive microorganisms.

Multifocal necrosis of the cerebellar folia was accompanied by numerous foamy macrophages combined with gemistocytic astrocytes (astrocytes with eosinophilic, abundant cytoplasm and an eccentric nucleus) and mononuclear inflammatory cells.

Immunohistochemistry studies in patients with Elejalde syndrome have demonstrated that 80% of lymphocytes in the inflammatory infiltrate are T cells. The significance of this is unclear because such findings can be found in diverse viral diseases or immunoallergic conditions.

Medical Care

Therapeutic measures for Elejalde syndrome patients have included the use of steroids, anticonvulsants, and antipyretics, and they have been unsuccessful in all patients. Thus, whether any medical therapy can be recommended for Elejalde syndrome patients is unclear.

Long-Term Monitoring

Substantial psychosocial implications are associated with pigmentary disorders, and these must be considered in patient care.[30]

Author

Noah S Scheinfeld, JD, MD, FAAD, † Assistant Clinical Professor, Department of Dermatology, Weil Cornell Medical College; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, New York Eye and Ear Infirmary; Assistant Attending Dermatologist, New York Presbyterian Hospital; Assistant Attending Dermatologist, Lenox Hill Hospital, North Shore-LIJ Health System; Private Practice

Disclosure: Nothing to disclose.

Coauthor(s)

Ann M Johnson, MD, Assistant Professor of Clinical Radiology, University of Pennsylvania School of Medicine; Director, Body MRI, Department of Radiology, Children’s Hospital of Philadelphia

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD, Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Disclosure: Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Allergen; Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Julie C Harper, MD, Assistant Program Director, Assistant Professor, Department of Dermatology, University of Alabama at Birmingham

Disclosure: Received honoraria from Stiefel for speaking and teaching; Received honoraria from Allergan for speaking and teaching; Received honoraria from Intendis for speaking and teaching; Received honoraria from Coria for speaking and teaching; Received honoraria from Sanofi-Aventis for speaking and teaching.

References

  1. Elejalde BR, Valencia A, Gilbert EF. Neuro-ectodermal melanolysosomal disease: an autosomal recessive pigment mutation in man [abstr]. Am J Hum Genet. 1977. 29:39A.
  2. Elejalde BR, Holguin J, Valencia A, et al. Mutations affecting pigmentation in man: I. Neuroectodermal melanolysosomal disease. Am J Med Genet. 1979. 3(1):65-80. [View Abstract]
  3. McKusick VA, Rasmussen SA. 256710 Neuroectodermal Melanolysosomal Disease. Online Mendelian Inheritance in Man. Available at http://www.ncbi.nlm.nih.gov/omim/256710. Accessed: March 26, 2003.
  4. Elejalde syndrome. Available at http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=33445. Accessed: June 21, 2009.
  5. Lee JY, Eldeeb MS, Hsu CK, Saito R, Abouzeid SA, McGrath JA. Further evidence for genotype-phenotype disparity in Griscelli syndrome. Br J Dermatol. 2016 Jul 15. [View Abstract]
  6. Galve J, Martín-Santiago A, Clavero C, Saus C, Alfaro-Arenas R, Pérez-Granero A, et al. Spontaneous repigmentation of silvery hair in an infant with congenital hydrops fetalis and hypoproteinemia. Cutis. 2016 Jun. 97 (6):E1-5. [View Abstract]
  7. Introne WJ, Westbroek W, Cullinane AR, Groden CA, Bhambhani V, Golas GA, et al. Neurologic involvement in patients with atypical Chediak-Higashi disease. Neurology. 2016 Apr 5. 86 (14):1320-8. [View Abstract]
  8. Gil-Krzewska A, Saeed MB, Oszmiana A, Fischer ER, Lagrue K, Gahl WA, et al. An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome. J Allergy Clin Immunol. 2017 Dec 11. [View Abstract]
  9. Cassandra L. Kniffin and Victor A. McKusick. Elejalde disease. Online Mendelian Inheritance in Man®. Available at http://www.omim.org/entry/256710. Accessed: January 17, 2014.
  10. Tey HL. A practical classification of childhood hypopigmentation disorders. Acta Derm Venereol. 2010. 90:6-11. [View Abstract]
  11. Tey HL. Approach to hypopigmentation disorders in adults. Clin Exp Dermatol. 2010 Apr 26. [View Abstract]
  12. Sahana M, Sacchidanand S, Hiremagalore R, Asha G. Silvery grey hair: clue to diagnose immunodeficiency. Int J Trichology. 2012 Apr. 4(2):83-5. [View Abstract]
  13. Cagdas D, Ozgür TT, Asal GT, et al. Griscelli syndrome types 1 and 3: analysis of four new cases and long-term evaluation of previously diagnosed patients. Eur J Pediatr. 2012 Oct. 171(10):1527-31. [View Abstract]
  14. Saini AG, Nagaraju S, Sahu JK, Rawat A, Vyas S, Singhi P. Teaching neuroImages: Griscelli syndrome and CNS lymphohistiocytosis. Neurology. 2014 Apr 8. 82(14):e122-3. [View Abstract]
  15. Dessinioti C, Stratigos AJ, Rigopoulos D, Katsambas AD. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol. 2009 Sep. 18(9):741-9. [View Abstract]
  16. Lambert J, Vancoillie G, Naeyaert JM. Elejalde syndrome revisited. Arch Dermatol. 2000 Jan. 136(1):120-1. [View Abstract]
  17. Sanal O, Yel L, Kucukali T, et al. An allelic variant of Griscelli disease: presentation with severe hypotonia, mental-motor retardation, and hypopigmentation consistent with Elejalde syndrome (neuroectodermal melanolysosomal disorder). J Neurol. 2000 Jul. 247(7):570-2. [View Abstract]
  18. Anikster Y, Huizing M, Anderson PD, et al. Evidence that Griscelli syndrome with neurological involvement is caused by mutations in RAB27A, not MYO5A. Am J Hum Genet. 2002 Aug. 71(2):407-14. [View Abstract]
  19. Wilson SM, Yip R, Swing DA, et al. A mutation in Rab27a causes the vesicle transport defects observed in ashen mice. Proc Natl Acad Sci U S A. 2000 Jul 5. 97(14):7933-8. [View Abstract]
  20. Li YR, Zhong A, Dong H, Ni LH, Tan FQ, Yang WX. Myosin Va plays essential roles in maintaining normal mitosis, enhancing tumor cell motility and viability. Oncotarget. 2017 Aug 15. 8 (33):54654-54671. [View Abstract]
  21. Wagner W, Brenowitz SD, Hammer JA 3rd. Myosin-Va transports the endoplasmic reticulum into the dendritic spines of Purkinje neurons. Nat Cell Biol. 2011 Jan. 13(1):40-8. [View Abstract]
  22. Miyata M, Kishimoto Y, Tanaka M, et al. A role for myosin Va in cerebellar plasticity and motor learning: a possible mechanism underlying neurological disorder in myosin Va disease. J Neurosci. 2011 Apr 20. 31(16):6067-78. [View Abstract]
  23. Afifi HH, Zaki MS, El-Kamah GY, El-Darouti M. Elejalde syndrome: clinical and histopathological findings in an Egyptian male. Genet Couns. 2007. 18(2):179-88. [View Abstract]
  24. Sori T, Nath AK, Thappa DM, Jaisankar TJ. Hypopigmentary disorders in children in South India. Indian J Dermatol. 2011 Sep-Oct. 56(5):546-9. [View Abstract]
  25. Duran-McKinster C, Rodriguez-Jurado R, Ridaura C, et al. Elejalde syndrome--a melanolysosomal neurocutaneous syndrome: clinical and morphological findings in 7 patients. Arch Dermatol. 1999 Feb. 135(2):182-6. [View Abstract]
  26. Ivanovich J, Mallory S, Storer T, Ciske D, Hing A. 12-year-old male with Elejalde syndrome (neuroectodermal melanolysosomal disease). Am J Med Genet. 2001 Feb 1. 98(4):313-6. [View Abstract]
  27. Chen CP. Syndromes and disorders associated with omphalocele (III): single gene disorders, neural tube defects, diaphragmatic defects and others. Taiwan J Obstet Gynecol. 2007 Jun. 46(2):111-20. [View Abstract]
  28. Raghuveer C, Murthy SC, Mithuna MN, Suresh T. Silvery Hair with Speckled Dyspigmentation: Chediak-Higashi Syndrome in Three Indian Siblings. Int J Trichology. 2015 Jul-Sep. 7 (3):133-5. [View Abstract]
  29. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012 Mar 22. 119(12):2754-63. [View Abstract]
  30. Rose PT. Pigmentary disorders. Med Clin North Am. 2009 Nov. 93(6):1225-39. [View Abstract]